CD4 and neoplasm: To this end, we utilized immunohistochemistry with custom-made VisioPharm (Version 2018.4) analysis apps to determine the percent of total tumor area with immunoreactivity to CD68, CD3, CD4, CD8a, neutrophil elastase, and CD45r.